Setting and Participants
Patients between 18 and 75 years old who met the inclusion criteria were
recruited into the study. They all voluntarily participated and signed
the informed consent form. The admission criteria were consistent with
primary bilateral CRSwNP from the EPOS 2020
guidelines5. Patients who had poor control of nasal
symptoms after 6-12 weeks of drug therapy and needed surgical
intervention were enrolled. Secondary CRS were excluded. Pregnant or
breastfeeding women were not included in the study.
All patients were registered in the inpatient department from March 2020
to January 2021 and were randomly assigned to three groups. Patients in
control group received conventional treatment (antibiotics for 3 days
and nasal corticosteriod and irrigation for 1 month) and placebo
(saline) nasal-spray twice per day after ESS. In the rh-bFGF nasal-spray
group, patients received conventional treatment and rh-bFGF nasal-spray
after ESS (4 sprays (1 spray=0.1 ml) twice per day). In the rh-bFGF
nasal-drop group, patients received conventional treatment and rh-bFGF
nasal-drops (0.4 ml twice per day). The patients in rh-bFGF nasal-drop
group were required to keep the posture of Mygind during
nasal-drops17. All enrolled patients received rh-bFGF
treatment for 1 month and were followed up for 1 year.